UBS Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $53

Benzinga Newsdesk www.benzinga.com Neutral 82.7%

Neg 0% Neu 82.7% Pos 0%

UBS analyst Alice Nettleton initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Neutral rating and announces Price Target of $53.